Feasibility of measuring sleep-dependent brain activity at home in people with prodromal and mild Alzheimer's disease to help delay symptoms (SleepAD)

niversity of Bristol0 sites100 target enrollmentStarted: March 22, 2023Last updated: April 3, 2023

Trial Snapshot

No summary available.

•For Sub-Study 1:
•1. Age > 50 years
•2. All participants must express that they are willing to take part in this study and adhere to the study procedures
•3. Full capacity to consent to involvement
•4. Clinical diagnosis of MCI due to AD or mild AD according to standardised criteria
•For Sub-Study 2:
•1. All participants undergoing CSF testing clinically including CSF biomarkers of AD.
•2. All participants must express that they are willing to take part in this study and adhere to the study procedures.
•3. Full capacity to consent to involvement

•For Sub-Study 1
•1. Severe medical or psychiatric co-morbidity, which, in the opinion of the investigator, may substantially impact on sleep.
•2. Clinically significant sleep disorder as defined by ICD-10 or equivalent pre-dating and / or not related to AD pathology.
•3. Diagnosis of dementia other than AD.
•4. Montreal Cognitive Assessment (MoCA) < 11/30
•For Sub-Study 2
•1. Severe medical or psychiatric co-morbidity, which, in the opinion of the investigator, may substantially impact on the ability to tolerate withdrawal of an extra 10ml of blood.

Sponsor

niversity of Bristol